Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 668-675

  Chrischilles, Elizabeth A ^a   Klepser, Donald G ^a   Brooks, John M ^a   Voelker, Margaret D ^a   Chen Hardee, Shari S ^a   Scott, Shane D ^c   Link, Brian K ^b   Delgado, David J ^d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d AMGEN INC   (United States)

Author keywords

And End Results Program; Epidemiology; HCUP; Healthcare Cost and Utilization Project; Hospitalization costs; Linked databases; Neutropenia; Non Hodgkin's lymphoma; SEER Program; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHARLSON SCORE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; DATA BASE; FEMALE; FOLLICULAR LYMPHOMA; HOSPITAL CARE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LARGE CELL LYMPHOMA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HOSPITAL COSTS; HUMANS; INPATIENTS; IOWA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; SEER PROGRAM; SEX FACTORS;

EID: 18044393205     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.668.63586     Document Type: Article

References (23)

1. Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization (NH) associated with chemotherapy [abstr]. Proc Am Soc Clin Oncol 2003;22:763.
2. Kuderer NM, Cosier L, Crawford J, Dale DC, Lyman GH, for the ANC Study Group. Mortality and economic impact of hospitalization with febrile neutropenia in patients with breast cancer: analysis of a nationwide database [abstr]. Proc Am Soc Clin Oncol 2003;22:27.
3. Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy 2001;21:684-90.
4. Lyman GH, Kuderer NM, Agboola O, Crawford J, Dale DC, for the ANC Study Group. The epidemiology and economics of neutropenia in hospitalized cancer patients: data from the university healthsystem consortium [abstr]. Blood 2001;98:432A.
5. Kuderer NM, Cosler L, Crawford J, Dale DC, Lyman GH. Cost and mortality associated with febrile neutropenia in adult cancer patients [abstr]. Proc Am Soc Clin Oncol 2002;21:250a.
6. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997;18:51-76.
7. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the southwest oncology group experience. J Clin Oncol 1986;4:295-305.
8. Epelbaum R, Haim N, Ben-Shahar M, et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma, Isr J Med Sci 1988;24:533-8.
9. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-77.
10. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (groupe d'etude des lymphomes de l'adulte). Ann Oncol 1993;4:651-6.
11. Gaynor ER, Dahlberg S, Fisher RI. Factors affecting reduced survival of the elderly with intermediate grade lymphoma: an analysis of SWOG-8516(INT 0067)-the national high priority lymphoma study, a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B [abstr]. Proc Annu Meet Am Soc Clin Oncol 1994;13:1250.
12. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M, for the OPPS Working Group and the ANC Study Group. Risk of first febrile neutropenia (FN) among patients receiving CHOP chemotherapy [abstr 1430]. Alexandria, VA: American Society of Clinical Oncology. 2002 ASCO annual meeting abstracts. Available from www.asco.org.
13. Chrischilles EA, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay and febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002;9:1-9.
14. Brooks JM, Chrischilles E, Scott S, et al. Information gained from linking SEER cancer registry data to state-level hospital discharge abstracts. Med Care 2000;38:1131-40.
15. Potosky AL, Riley GF, Lubitz JD, et al. Potential of cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
16. Center for Medicare and Medicaid Services. 1999 Medicare impact file. Available from http://www.cms.hhs.gov/providers/hipps/ippspufs.asp. Accessed July 2002.
17. Deyo RA, Gherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
18. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47-56.
19. Chrischilles EA, Chen-Hardee S, Voelker MD, et al. Time to first neutropenia hospitalization during chemotherapy for non-Hodgkin's lymphoma: an Iowa SEER-Medicare study [abstr]. Proc Am Soc Clin Oncol 2003;22:763.
20. Voelker MD, Rubenstein LM, Chrischilles EA, et al. Time to first neutropenia hospitalization during first course chemotherapy among newly diagnosed non-Hodgkin's lymphoma patients: national SEER-Medicare study. Presented at the 45th annual meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003.
21. Brooks JM, Voelker MD, Chen-Hardee SS. Neutropenia-related inpatient Medicare costs during first course chemotherapy among newly diagnosed non-Hodgkin's lymphoma patients: national SEER-Medicare study. Presented at the 45th annual meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003.
22. Martelli M, De Sanctis V, Awtsati G, et al. Current guidelines for the management of aggressive non-Hodgkin's lymphoma. Drugs 1997;53:957-72.
23. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care 2002;40:201-11.